Stories

HKBU-led research team develops novel anti-viral targeted drug for nasopharyngeal cancer treatment

A research team led by Hong Kong Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumours caused by the virus. It is the first known agent to successfully target the virus and disturb its latency in tumour cells in this way.

Previous
1 2
3 4 5 6 Next

Yelem | initiative

Are you sure you want to remove this information?

Are you sure that you have done uploading?